More Cspc Pharmaceutical Group Limited news
Cspc Pharmaceutical Group LimitedHKEX: 1093

Voluntary announcement - recombinant herpes zoster vaccine (sys6052) obtains clinical trial approval in the U.S.

Sep 29, 2026 at 10:00 AM UTC · Issued by Cspc Pharmaceutical Group Limited via HKEXnews

HKEX: 1093

View Attachment

View original source (HKEXnews)

Earlier from Cspc Pharmaceutical

  • Voluntary announcement - sys6077 injection obtains clinical trial approval in chinaSep 28
  • Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary EndpointApr 1
  • Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast CancerMar 24
  • Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003Feb 14
All Cspc Pharmaceutical news releases↗